Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Effient | Prasugrel | Acute coronary syndrome | Do not list | Complete | ||
| Saphris | Asenapine | Bipolar I disorder | List with clinical criteria and/or conditions | Complete | ||
| Zelboraf | Vemurafenib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Yervoy | Ipilimumab | Advanced Melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| ASMANEX | Mometasone furoate | Asthma | List | Complete | ||
| Sutent | Sunitinib malate | Pancreatic Neuroendocrine Tumour | Reimburse with clinical criteria and/or conditions | Complete | ||
| Gelnique | Oxybutynin Chloride Gel | Overactive bladder | Do not list | Complete | ||
| RAPAFLO | Silodosin | Benign prostatic hyperplasia | Do not list | Complete | ||
| Xarelto | Rivaroxaban | Atrial fibrillation, stroke prevention | List with clinical criteria and/or conditions | Complete | ||
| COMPLERA | Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate | HIV infection | List | Complete |
Last Updated : May 11, 2024